Skip to main content
Premium Trial:

Request an Annual Quote

Tethys Bioscience Nabs $25M in New Financing

This story has been updated from a previous version, which inadvertently omitted Aeris Capital as an investor.

NEW YORK (GenomeWeb News) – Tethys Bioscience has closed $25 million in Series D financing, which it plans to use to expand commercialization of its PreDx Diabetes Risk Score test.

The funding round was led by Aeris Capital, and included current investors MDV-Mohr Davidow Ventures, Kleiner Perkins Caulfield and Byers, and Intel Capital; and one new investor, Wasatch Advisors.

The firm said that the blood-based test will identify individuals who are at the highest risk of developing type 2 diabetes within five years.

Company CEO and Chairman Mickey Urdea said in a statement that the Tethys will use the capital to meet demand from primary care doctors through new commercialization strategies.

“To enhance the clinician’s experience and effectiveness with the PreDx DRS, we are also developing a diabetes risk-reduction initiative, which will help them to educate their high-risk patients about critical lifestyle and behavioral changes that may help prevent the development of diabetes,” Urdea said.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.